Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Dionex Corp. (“Dionex” or the “Company”) (NASDAQ: DNEX) concerning the proposed acquisition of the Company by Thermo Fisher Scientific. Under the terms of the offer, Dionex shareholders will receive $118.50 in cash for each share that they own. The transaction is valued at approximately $2.1 billion.

The investigation is focused on the potential unfairness of the deal price to Dionex shareholders, the process by which the Dionex Board of Directors considered the transaction, and potential conflicts of interests on the part of Dionex Board members. Dionex recently announced solid sales and earnings per share growth in the first quarter ended September 30, 2010.

If you are interested in discussing your rights as a Dionex shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010